Shares of Arcturus Therapeutics Holdings Inc. (ARCT) have lost approximately 78% from their 52-week high of $45, recorded last June, and now trade around $9.70.
This commercial mRNA medicines and vaccines company has several key catalysts lined up this quarter that could reshape the narrative - most notably, those related to ARCT-032, ARCT-810, and Kostaive.
-- ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR gene in the lungs of individuals with cystic fibrosis.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.